Abstract
Summary
Idiopathic pulmonary fibrosis (Idiopathic pulmonary fibrosis, IPF) is a rare, chronic, and fatal disease that will gradually develop over a period of several years. It is typically characterized by the formation of scar tissue in the lungs and progressive dyspnea. It is the most common type of interstitial lung disease in idiopathic interstitial pneumonia. Its clinical features include shortness of breath, diffuse lung infiltrates on imaging, and lung biopsy showing varying degrees of inflammation/fibrosis or Both.
The global market for Idiopathic Pulmonary Fibrosis Disease Treatment was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Idiopathic Pulmonary Fibrosis Disease Treatment, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Idiopathic Pulmonary Fibrosis Disease Treatment by region & country, by Type, and by Application.
The Idiopathic Pulmonary Fibrosis Disease Treatment market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Idiopathic Pulmonary Fibrosis Disease Treatment.
Market Segmentation
By Company
Boehringer Ingelheim
Merck and Co., Inc.
ArkBio
Zelgen
Blade Therapeutics
Regend Therapeutics (Cayman) Ltd.
Insilico Medicine
Vicore Pharma
Heilongjiang Zbd Pharmaceutical
Indaco
InterMune, Inc.
Bristol Myers Squibb
SHIONOGI & CO., Ltd.
Segment by Type:
Pirfenidone
Nintedanib
Other
Segment by Application
Hospital
Graduate School
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Idiopathic Pulmonary Fibrosis Disease Treatment manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Idiopathic Pulmonary Fibrosis Disease Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Idiopathic Pulmonary Fibrosis Disease Treatment in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
The global market for Idiopathic Pulmonary Fibrosis Disease Treatment was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Idiopathic Pulmonary Fibrosis Disease Treatment, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Idiopathic Pulmonary Fibrosis Disease Treatment by region & country, by Type, and by Application.
The Idiopathic Pulmonary Fibrosis Disease Treatment market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Idiopathic Pulmonary Fibrosis Disease Treatment.
Market Segmentation
By Company
Boehringer Ingelheim
Merck and Co., Inc.
ArkBio
Zelgen
Blade Therapeutics
Regend Therapeutics (Cayman) Ltd.
Insilico Medicine
Vicore Pharma
Heilongjiang Zbd Pharmaceutical
Indaco
InterMune, Inc.
Bristol Myers Squibb
SHIONOGI & CO., Ltd.
Segment by Type:
Pirfenidone
Nintedanib
Other
Segment by Application
Hospital
Graduate School
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Idiopathic Pulmonary Fibrosis Disease Treatment manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Idiopathic Pulmonary Fibrosis Disease Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Idiopathic Pulmonary Fibrosis Disease Treatment in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
1.1 Idiopathic Pulmonary Fibrosis Disease Treatment Product Introduction
1.2 Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Forecast
1.3 Idiopathic Pulmonary Fibrosis Disease Treatment Market Trends & Drivers
1.3.1 Idiopathic Pulmonary Fibrosis Disease Treatment Industry Trends
1.3.2 Idiopathic Pulmonary Fibrosis Disease Treatment Market Drivers & Opportunity
1.3.3 Idiopathic Pulmonary Fibrosis Disease Treatment Market Challenges
1.3.4 Idiopathic Pulmonary Fibrosis Disease Treatment Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Idiopathic Pulmonary Fibrosis Disease Treatment Players Revenue Ranking (2023)
2.2 Global Idiopathic Pulmonary Fibrosis Disease Treatment Revenue by Company (2019-2024)
2.3 Key Companies Idiopathic Pulmonary Fibrosis Disease Treatment Manufacturing Base Distribution and Headquarters
2.4 Key Companies Idiopathic Pulmonary Fibrosis Disease Treatment Product Offered
2.5 Key Companies Time to Begin Mass Production of Idiopathic Pulmonary Fibrosis Disease Treatment
2.6 Idiopathic Pulmonary Fibrosis Disease Treatment Market Competitive Analysis
2.6.1 Idiopathic Pulmonary Fibrosis Disease Treatment Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Idiopathic Pulmonary Fibrosis Disease Treatment Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Idiopathic Pulmonary Fibrosis Disease Treatment as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Pirfenidone
3.1.2 Nintedanib
3.1.3 Other
3.2 Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Type
3.2.1 Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value, by Type (2019-2030)
3.2.3 Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital
4.1.2 Graduate School
4.1.3 Others
4.2 Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Application
4.2.1 Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value, by Application (2019-2030)
4.2.3 Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Region
5.1.1 Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Region (2019-2024)
5.1.3 Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Region (2025-2030)
5.1.4 Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value, 2019-2030
5.2.2 North America Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value, 2019-2030
5.3.2 Europe Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value, 2019-2030
5.4.2 Asia Pacific Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value, 2019-2030
5.5.2 South America Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value, 2019-2030
5.6.2 Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value
6.3 United States
6.3.1 United States Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value, 2019-2030
6.3.2 United States Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value, 2019-2030
6.4.2 Europe Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value, 2019-2030
6.5.2 China Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Type (%), 2023 VS 2030
6.5.3 China Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value, 2019-2030
6.6.2 Japan Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value, 2019-2030
6.7.2 South Korea Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value, 2019-2030
6.8.2 Southeast Asia Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value, 2019-2030
6.9.2 India Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Type (%), 2023 VS 2030
6.9.3 India Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Boehringer Ingelheim
7.1.1 Boehringer Ingelheim Profile
7.1.2 Boehringer Ingelheim Main Business
7.1.3 Boehringer Ingelheim Idiopathic Pulmonary Fibrosis Disease Treatment Products, Services and Solutions
7.1.4 Boehringer Ingelheim Idiopathic Pulmonary Fibrosis Disease Treatment Revenue (US$ Million) & (2019-2024)
7.1.5 Boehringer Ingelheim Recent Developments
7.2 Merck and Co., Inc.
7.2.1 Merck and Co., Inc. Profile
7.2.2 Merck and Co., Inc. Main Business
7.2.3 Merck and Co., Inc. Idiopathic Pulmonary Fibrosis Disease Treatment Products, Services and Solutions
7.2.4 Merck and Co., Inc. Idiopathic Pulmonary Fibrosis Disease Treatment Revenue (US$ Million) & (2019-2024)
7.2.5 Merck and Co., Inc. Recent Developments
7.3 ArkBio
7.3.1 ArkBio Profile
7.3.2 ArkBio Main Business
7.3.3 ArkBio Idiopathic Pulmonary Fibrosis Disease Treatment Products, Services and Solutions
7.3.4 ArkBio Idiopathic Pulmonary Fibrosis Disease Treatment Revenue (US$ Million) & (2019-2024)
7.3.5 Zelgen Recent Developments
7.4 Zelgen
7.4.1 Zelgen Profile
7.4.2 Zelgen Main Business
7.4.3 Zelgen Idiopathic Pulmonary Fibrosis Disease Treatment Products, Services and Solutions
7.4.4 Zelgen Idiopathic Pulmonary Fibrosis Disease Treatment Revenue (US$ Million) & (2019-2024)
7.4.5 Zelgen Recent Developments
7.5 Blade Therapeutics
7.5.1 Blade Therapeutics Profile
7.5.2 Blade Therapeutics Main Business
7.5.3 Blade Therapeutics Idiopathic Pulmonary Fibrosis Disease Treatment Products, Services and Solutions
7.5.4 Blade Therapeutics Idiopathic Pulmonary Fibrosis Disease Treatment Revenue (US$ Million) & (2019-2024)
7.5.5 Blade Therapeutics Recent Developments
7.6 Regend Therapeutics (Cayman) Ltd.
7.6.1 Regend Therapeutics (Cayman) Ltd. Profile
7.6.2 Regend Therapeutics (Cayman) Ltd. Main Business
7.6.3 Regend Therapeutics (Cayman) Ltd. Idiopathic Pulmonary Fibrosis Disease Treatment Products, Services and Solutions
7.6.4 Regend Therapeutics (Cayman) Ltd. Idiopathic Pulmonary Fibrosis Disease Treatment Revenue (US$ Million) & (2019-2024)
7.6.5 Regend Therapeutics (Cayman) Ltd. Recent Developments
7.7 Insilico Medicine
7.7.1 Insilico Medicine Profile
7.7.2 Insilico Medicine Main Business
7.7.3 Insilico Medicine Idiopathic Pulmonary Fibrosis Disease Treatment Products, Services and Solutions
7.7.4 Insilico Medicine Idiopathic Pulmonary Fibrosis Disease Treatment Revenue (US$ Million) & (2019-2024)
7.7.5 Insilico Medicine Recent Developments
7.8 Vicore Pharma
7.8.1 Vicore Pharma Profile
7.8.2 Vicore Pharma Main Business
7.8.3 Vicore Pharma Idiopathic Pulmonary Fibrosis Disease Treatment Products, Services and Solutions
7.8.4 Vicore Pharma Idiopathic Pulmonary Fibrosis Disease Treatment Revenue (US$ Million) & (2019-2024)
7.8.5 Vicore Pharma Recent Developments
7.9 Heilongjiang Zbd Pharmaceutical
7.9.1 Heilongjiang Zbd Pharmaceutical Profile
7.9.2 Heilongjiang Zbd Pharmaceutical Main Business
7.9.3 Heilongjiang Zbd Pharmaceutical Idiopathic Pulmonary Fibrosis Disease Treatment Products, Services and Solutions
7.9.4 Heilongjiang Zbd Pharmaceutical Idiopathic Pulmonary Fibrosis Disease Treatment Revenue (US$ Million) & (2019-2024)
7.9.5 Heilongjiang Zbd Pharmaceutical Recent Developments
7.10 Indaco
7.10.1 Indaco Profile
7.10.2 Indaco Main Business
7.10.3 Indaco Idiopathic Pulmonary Fibrosis Disease Treatment Products, Services and Solutions
7.10.4 Indaco Idiopathic Pulmonary Fibrosis Disease Treatment Revenue (US$ Million) & (2019-2024)
7.10.5 Indaco Recent Developments
7.11 InterMune, Inc.
7.11.1 InterMune, Inc. Profile
7.11.2 InterMune, Inc. Main Business
7.11.3 InterMune, Inc. Idiopathic Pulmonary Fibrosis Disease Treatment Products, Services and Solutions
7.11.4 InterMune, Inc. Idiopathic Pulmonary Fibrosis Disease Treatment Revenue (US$ Million) & (2019-2024)
7.11.5 InterMune, Inc. Recent Developments
7.12 Bristol Myers Squibb
7.12.1 Bristol Myers Squibb Profile
7.12.2 Bristol Myers Squibb Main Business
7.12.3 Bristol Myers Squibb Idiopathic Pulmonary Fibrosis Disease Treatment Products, Services and Solutions
7.12.4 Bristol Myers Squibb Idiopathic Pulmonary Fibrosis Disease Treatment Revenue (US$ Million) & (2019-2024)
7.12.5 Bristol Myers Squibb Recent Developments
7.13 SHIONOGI & CO., Ltd.
7.13.1 SHIONOGI & CO., Ltd. Profile
7.13.2 SHIONOGI & CO., Ltd. Main Business
7.13.3 SHIONOGI & CO., Ltd. Idiopathic Pulmonary Fibrosis Disease Treatment Products, Services and Solutions
7.13.4 SHIONOGI & CO., Ltd. Idiopathic Pulmonary Fibrosis Disease Treatment Revenue (US$ Million) & (2019-2024)
7.13.5 SHIONOGI & CO., Ltd. Recent Developments
8 Industry Chain Analysis
8.1 Idiopathic Pulmonary Fibrosis Disease Treatment Industrial Chain
8.2 Idiopathic Pulmonary Fibrosis Disease Treatment Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Idiopathic Pulmonary Fibrosis Disease Treatment Sales Model
8.5.2 Sales Channel
8.5.3 Idiopathic Pulmonary Fibrosis Disease Treatment Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer